You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Choroidal Neovascular Membrane,

Showing 51 - 75 of 3,017
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Angioid Streaks of Macula Trial in Mykolaiv, Odessa (Intravitreal injection)

Recruiting
  • Angioid Streaks of Macula
  • Intravitreal injection
  • Mykolaiv, Ukraine
  • +2 more
Feb 2, 2021

Rate of Pseudoxanthoma Elasticum-associated Choroidal and

Recruiting
  • Pseudoxanthoma Elasticum
  • No intervention
  • Basel, Basel-Stadt, Switzerland
    University Hospital Basel
Dec 21, 2022

Neovascular Age-related Macular Degeneration Trial in Worldwide (brolucizumab)

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • Huntington Beach, California
  • +59 more
Jan 20, 2023

Macular Degeneration Trial in Worldwide (Ranibizumab)

Completed
  • Macular Degeneration
  • Ranibizumab
  • Gilbert, Arizona
  • +101 more
Mar 11, 2022

Macular Degeneration Trial in United Kingdom (Epimacular Brachytherapy, Ranibizumab)

Completed
Has Results
  • Macular Degeneration
  • Exeter, Devon, United Kingdom
  • +23 more
Nov 23, 2020

Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization Trial in Fort Worth (Brolucizumab ophthalmic

Completed
Has Results
  • Neovascular Age-Related Macular Degeneration
  • Choroidal Neovascularization
  • Brolucizumab ophthalmic solution
  • Aflibercept ophthalmic solution
  • Fort Worth, Texas
    Contact Alcon Call Center for Trial Locations
Jan 8, 2020

Age-related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration Trial in Germany, Switzerland (Brolucizumab)

Recruiting
  • Age-related Macular Degeneration
  • +5 more
  • Brolucizumab
  • Regensburg, Bavaria, Germany
  • +32 more
Jan 20, 2023

Neovascular Macular Degeneration Trial in Worldwide (Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne)

Completed
Has Results
  • Neovascular Macular Degeneration
  • Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
  • Visudyne
  • Liverpool, New South Wales, Australia
  • +61 more
Nov 17, 2020

Patients Receiving Beovu in Neovascular Age-related Macular

Recruiting
  • Neovascular Age-related Macular Degeneration (nAMD)
  • Luedenscheid, NRW, Germany
  • +48 more
Sep 16, 2022

Neovascular Age-related Macular Degeneration Trial in United States (ADVM-022)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • ADVM-022
  • Phoenix, Arizona
  • +4 more
Sep 8, 2022

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Enrolling by invitation
  • Wet Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • ADVM-022
  • Bakersfield, California
  • +8 more
Dec 23, 2021

Choroidal Thickness Vitrectomy

Completed
  • Epiretinal Membrane
    • Vienna, Austria
      Department of Ophthalmology, Medical University of Vienna, Austr
    Oct 15, 2019

    Corneal Transplantation, Glaucoma and Ocular Hypertension, Postoperative Complications Trial in Montréal (Boston

    Recruiting
    • Corneal Transplantation
    • +4 more
    • Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy
    • Montréal, Quebec, Canada
      Centre Hospitalier de l'Université de Montréal (CHUM)
    Jul 4, 2022

    Wet Macular Degeneration Trial in Worldwide (KSI-301, Aflibercept, Sham Procedure)

    Terminated
    • Wet Macular Degeneration
    • Phoenix, Arizona
    • +74 more
    Jun 2, 2022

    Neovascular Age-Related Macular Degeneration Trial in United States (PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal

    Completed
    Has Results
    • Neovascular Age-Related Macular Degeneration
    • PDS Implant filled with 100 mg/mL Ranibizumab
    • Intravitreal Injections of 10 mg/mL Ranibizumab
    • Mesa, Arizona
    • +76 more
    Feb 28, 2022

    Neovascular Age-related Macular Degeneration Trial (PMC-403)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • (no location specified)
    Jul 11, 2023

    Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration Trial in United States (ADVM-022)

    Active, not recruiting
    • Wet Age-related Macular Degeneration
    • Neovascular Age-related Macular Degeneration
    • ADVM-022
    • Bakersfield, California
    • +10 more
    Mar 21, 2022

    Neovascular Age-related Macular Degeneration Trial in Worldwide (SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL))

    Active, not recruiting
    • Neovascular Age-related Macular Degeneration
    • SOK583A1 (40 mg/mL)
    • Eylea EU (40 mg/mL)
    • Phoenix, Arizona
    • +101 more
    Jan 23, 2023

    Diabetes, Type 2, Diabetic Retinopathy Trial (RLRL device)

    Not yet recruiting
    • Diabetes Mellitus, Type 2
    • Diabetic Retinopathy
    • RLRL device
    • (no location specified)
    Mar 19, 2023

    Choroidal Melanoma Trial in Aurora (1000CsK Silicon Oil Tamponade)

    Completed
    • Choroidal Melanoma
    • 1000CsK Silicon Oil Tamponade
    • Aurora, Colorado
      University of Colorado Eye Center
    Mar 4, 2022

    Myopia, Myopia Progression, Juvenile Myopia Trial in Waterloo (Diffusion Optics Technology (DOT) Pattern Spectacle Lens, Control

    Not yet recruiting
    • Myopia
    • +2 more
    • Diffusion Optics Technology (DOT) Pattern Spectacle Lens
    • Control Spectacle Lens
    • Waterloo, Ontario, Canada
      Centre for Ocular Research and Education
    Dec 5, 2022

    Neovascular Age-related Macular Degeneration Trial in United States (OLX10212 is a cell penetrating asymmetric small

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
    • Santa Maria, California
    • +4 more
    Jan 10, 2023

    Neovascular Age-related Macular Degeneration Trial in Seongnam-si (Probiotic Combination Cap/Tab, intravitreal Anti-VEGF

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • Probiotic Combination Cap/Tab
    • intravitreal Anti-VEGF injection
    • Seongnam-si, Korea, Republic of
      Seoul National University Bundang Hospital
    Nov 1, 2022

    Neovascular Age-related Macular Degeneration Trial in Worldwide (2.0 mg OPT-302, 2.0 aflibercept, Sham)

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • 2.0 mg OPT-302
    • +2 more
    • Phoenix, Arizona
    • +182 more
    Sep 6, 2022

    Neovascular Age-related Macular Degeneration Trial in Worldwide (2.0 mg OPT-302, 0.5 mg ranibizumab, Sham)

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • 2.0 mg OPT-302
    • +2 more
    • Phoenix, Arizona
    • +174 more
    Sep 6, 2022